Description: Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Home Page: www.athersys.com
ATHX Technical Analysis
3201 Carnegie Avenue
Cleveland,
OH
44115-2634
United States
Phone:
216 431 9900
Officers
| Name | Title |
|---|---|
| Mr. Daniel A. Camardo M.B.A. | CEO, Sec., Principal Accounting Officer & Director |
| Ms. Z. Kasey Rosado | Interim Chief Financial Officer |
| Ms. Maia A. Hansen M.B.A., M.S. | Chief Operating Officer |
| Ms. Alison O'Sullivan M.B.A. | VP of HR |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Exec. VP & Head of Global Regulatory Affairs |
| Dr. Robert Mays Ph.D. | Exec. VP, Head of Regenerative Medicine & Neuroscience Programs |
| Mr. Rakesh Ramachandran MS | Head of Information Technology & Communications and VP |
| Mr. James Glover B.S., P.M.P. | Exec. VP & Head of Manufacturing |
| Ms. Ellen Gurley | Mang. of Corp. Communications and Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0.8594 |
|---|---|
| Trailing PE: | 0.7622 |
| Price-to-Book MRQ: | 219.5723 |
| Price-to-Sales TTM: | 2.3399 |
| IPO Date: | 2007-06-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 104 |